As of 2026-10-23, the EV/EBITDA ratio of Fulcrum Therapeutics Inc (FULC) is -3.78. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FULC's latest enterprise value is 196.73 mil USD. FULC's TTM EBITDA according to its financial statements is -52.05 mil USD. Dividing these 2 quantities gives us the above FULC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-10-20 | -3.83 |
| 2026-10-19 | -3.81 |
| 2026-10-16 | -3.74 |
| 2026-10-15 | -3.77 |
| 2026-10-14 | -3.77 |
| 2026-10-13 | -3.78 |
| 2026-10-12 | -3.87 |
| 2026-10-09 | -3.90 |
| 2026-10-08 | -3.87 |
| 2026-10-07 | -3.77 |
| 2026-10-06 | -3.79 |
| 2026-10-05 | -3.82 |
| 2026-10-02 | -3.79 |
| 2026-10-01 | -3.78 |
| 2026-09-30 | -3.81 |
| 2026-09-29 | -3.81 |
| 2026-09-28 | -3.83 |
| 2026-09-25 | -3.86 |
| 2026-09-24 | -3.91 |
| 2026-09-23 | -3.95 |
| 2026-09-22 | -3.98 |
| 2026-09-21 | -3.93 |
| 2026-09-18 | -3.88 |
| 2026-09-17 | -3.90 |
| 2026-09-16 | -3.92 |
| 2026-09-15 | -3.91 |
| 2026-09-14 | -3.92 |
| 2026-09-11 | -3.93 |
| 2026-09-10 | -3.93 |
| 2026-09-09 | -3.98 |
| 2026-09-08 | -3.96 |
| 2026-09-04 | -4.00 |
| 2026-09-03 | -3.98 |
| 2026-09-02 | -4.00 |
| 2026-09-01 | -4.02 |
| 2026-08-31 | -4.05 |
| 2026-08-28 | -4.00 |
| 2026-08-27 | -4.00 |
| 2026-08-26 | -4.01 |
| 2026-08-25 | -4.01 |
| 2026-08-24 | -3.98 |
| 2026-08-21 | -3.97 |
| 2026-08-20 | -4.00 |
| 2026-08-19 | -4.07 |
| 2026-08-18 | -4.02 |
| 2026-08-17 | -3.98 |
| 2026-08-14 | -3.86 |
| 2026-08-13 | -3.82 |
| 2026-08-12 | -3.83 |
| 2026-08-11 | -3.79 |